MFG
NMTR

Magnus Financial Group’s 9 Meters Biopharma NMTR Stock Holding History

Magnus Financial Group’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,475
Closed -$114K – 545
2018
Q4 		$114K Buy
+2,475
New +$183K 0.03% 394

Other funds holding NMTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Magnus Financial Group's NMTR Position: Q1 2019 in Review

Magnus Financial Group sold out of 9 Meters Biopharma (NMTR) in Q1 2019, closing a stake of 2,475 shares — an estimated $114K sold.

Magnus Financial Group first reported a position in NMTR in Q4 2018 and held it in 1 quarter. The position peaked at $114K in Q4 2018. 38 funds tracked by Wall St. Rank hold NMTR as of Q1 2019.

  • Magnus Financial Group reported no remaining 9 Meters Biopharma position as of Q1 2019 after selling out during the quarter.
  • Magnus Financial Group sold 2,475 9 Meters Biopharma shares in Q1 2019, an estimated $114K.
  • Magnus Financial Group first reported a position in 9 Meters Biopharma in Q4 2018 and held it in 1 quarter.
  • Magnus Financial Group's 9 Meters Biopharma position peaked at $114K in Q4 2018.
  • 38 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2019.

Based on Magnus Financial Group's 13F filing for Q1 2019, filed 9 May 2019.